Key Highlights
- BIXT shares rose on a sub-penny stock where a move can amount to a fraction of a cent and a few thousand shares changing hands.
- Bioxytran's lead oxygen-transport candidate BXT-25 targets stroke-related hypoxia, alongside ProLectin-M, a broad-spectrum antiviral in Phase 2 testing.
- Market Cap: near $3 million, with the stock trading around $0.025 and a 52-week range spanning roughly two cents to about a dime.
- The company completed a $1.2 million private Placement to fund operations, a modest sum for a company operating with roughly two employees.
On a sub-penny stock, a move can amount to a fraction of a cent and a few thousand shares changing hands. That is the context for Bioxytran, Inc. (OTC: BIXT), a tiny over-the-counter biotechnology company whose share price sits around two and a half cents and whose entire Market Value is only a few million dollars. For a name this small and this thinly traded, the day-to-day tape reveals little; the more meaningful story is the company's early-stage science and the fragile financial footing behind it.
Company and Latest Development
Bioxytran is a clinical-stage biotechnology company founded in 2008 and based in the healthcare sector, with a workforce of roughly two employees. It develops therapeutic drugs aimed at viral infections, oxygen delivery and degenerative diseases. Its lead oxygen-transport candidate, BXT-25, is an oxygen-carrying molecule designed to address stroke-related hypoxia and complications in wound healing. Alongside that program, Bioxytran has advanced ProLectin-M, a broad-spectrum antiviral, through Phase 2 testing, and it has reported securing camel-hemoglobin sourcing to support its oxygen-carrier work. The company has also cited research collaborations with the University of Minnesota and the University of Georgia.
What Is Driving Attention Around BIXT?
No verified, company-specific catalyst underlies recent trading. BIXT carries no analyst rating and trades on the OTC market, where a small order can produce an outsized percentage change. There is no confirmed clinical readout, regulatory decision, financing or Partnership tied to any single-session move. The realistic interpretation is that a modest percentage move reflects the mechanics of an illiquid, sub-penny security rather than fresh news. Investors reacting to a screener alert are responding to price data, not to a substantive development from the company.
Key Numbers and Company Position
The stock has traded around $0.025, giving it a market Capitalization near $3 million. Over the trailing year the shares have fallen sharply, and the 52-week range spans from roughly two cents to about a dime. To fund operations, Bioxytran completed a $1.2 million private placement, a modest sum that nonetheless matters for a company of this size. With only two employees and a nano-cap valuation, the company operates on a shoestring, and its progress depends heavily on external financing and research partnerships rather than internal cash generation.
What Could Come Next?
Because disclosure at this scale is limited, the items worth monitoring are foundational. They include any further data or regulatory steps for the ProLectin-M antiviral program, progress on the BXT-25 oxygen-carrier candidate and its camel-hemoglobin Supply chain, updates from the university research collaborations, and additional financing to extend the company's runway. Given the sub-penny price, any share-count actions such as reverse splits or new capital raises would be material to existing holders.
Risks to Watch
The risks are considerable. OTC sub-penny stocks carry heightened liquidity, Volatility and transparency risks, and a market value of only a few million dollars offers little cushion. Clinical-stage Assets can fail, and Bioxytran's early programs are far from commercialization. With minimal cash and a two-person team, the company faces significant funding and execution risk, and further capital raises could dilute existing shareholders.
Thin Trading, Not Fresh News, Explains BIXT's Recent Move
Bioxytran is a nano-cap OTC biotech defined more by its tiny size and illiquidity than by any confirmed catalyst. The verified picture shows an early-stage pipeline in antivirals and oxygen delivery, a small private placement and a sub-penny share price. Rather than a momentum setup, recent moves appear rooted in thin trading. Investors may be watching for progress on ProLectin-M and BXT-25, fresh financing, and any corporate actions that could reshape the capital structure.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...